Profile
Sector:
HealthcareCountry:
United StatesIPO:
19 February 2004Website:
http://www.dynavax.comNext earnings report:
21 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Sat, 16 Nov 2024 00:16:57 GMTDividend
Analysts recommendations
Institutional Ownership
DVAX Latest News
Today, we revisit Dynavax Technologies Corporation, whose shares have moved up nicely after the company announced a significant buyback authorization. In addition, DVAX's flagship product Heplisav-B continues to increase market share consistently in a growing market. The company has also moved towards profitability and analyst firms have price targets significantly above the current trading level of the stock, even after its recent rally.
Dynavax Technologies (DVAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The consensus price target hints at an 88.3% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
EMERYVILLE, Calif. , Nov. 11, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it has entered into an Accelerated Share Repurchase transaction ("ASR") under an agreement with Goldman Sachs & Co. LLC to repurchase $100 million of the Company's common stock.
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Dynavax Technologies Corporation (Nasdaq: DVAX) concerning the Company and its directors' and officers' possible violations of state laws. If you own Dynavax stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 358, New York, NY 1016.
EMERYVILLE, Calif. , Oct. 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2024 financial results on Thursday, November 7, 2024, after the U.S. financial markets close.
Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity, benefiting the sector. One way I have kept my biotech portfolio churning out profits is by embracing using covered call orders to establish positions in small-cap biotech names. Many of these have become consistent profitable “rinse, wash and repeat” trades over the years.
Dynavax has experienced fluctuations in stock performance since the author's initial coverage. HEPLISAV-B is Dynavax's primary revenue source for the foreseeable future, with CpG-1018 currently sidelined. Supported by ample liquidity, Dynavax is evaluating business development on a disciplined basis.
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to a 136% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Dynavax Technologies (DVAX) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.03 per share a year ago.
- 1(current)
- 2
What type of business is Dynavax Technologies?
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.
What sector is Dynavax Technologies in?
Dynavax Technologies is in the Healthcare sector
What industry is Dynavax Technologies in?
Dynavax Technologies is in the Drug Manufacturers - Specialty & Generic industry
What country is Dynavax Technologies from?
Dynavax Technologies is headquartered in United States
When did Dynavax Technologies go public?
Dynavax Technologies initial public offering (IPO) was on 19 February 2004
What is Dynavax Technologies website?
https://www.dynavax.com
Is Dynavax Technologies in the S&P 500?
No, Dynavax Technologies is not included in the S&P 500 index
Is Dynavax Technologies in the NASDAQ 100?
No, Dynavax Technologies is not included in the NASDAQ 100 index
Is Dynavax Technologies in the Dow Jones?
No, Dynavax Technologies is not included in the Dow Jones index
When was Dynavax Technologies the previous earnings report?
No data
When does Dynavax Technologies earnings report?
The next expected earnings date for Dynavax Technologies is 21 February 2025